PSMA PET watch for 2022, page-2

Thanks!

https://newsroom.clevelandclinic.org/2022/02/16/cleveland-clinic-unveils-top-10-medical-innovations-for-2022/

https://consultqd.clevelandclinic.org/top-10-medical-innovations-for-2022-unveiled/

Next-generation mRNA vaccines. A new approach for treating prostate cancer. Novel therapy for reducing LDL. These are three of the breakthrough technologies that will change healthcare in 2022, according to a panel of Cleveland Clinic physicians and researchers led by D. Geoffrey Vince, PhD, Executive Director of Innovations and Chair of Biomedical Engineering.

“At Cleveland Clinic, a shared passion for the delivery of superior care and an embedded culture of innovation foster continuous healthcare improvement dialogue among our clinicians and researchers,” says Dr. Vince. “As such, our experts always have their finger on the pulse of new technologies slated to change the face of healthcare. The Top 10 Medical Innovations program was launched to share their insight with the broader healthcare community, and year after year, our professionals continue to successfully predict device, technology and therapy advances.

”Here, in order of anticipated importance, are the Top 10 Medical Innovations for 2022:

1. Next generation of mRNA vaccinology



Advancements in the generation, purification and cellular delivery of RNA have enabled the development of RNA therapies across a broad array of applications, such as cancer and Zika virus. The technology is cost-effective and relatively simple to manufacture. Furthermore, the COVID-19 pandemic demonstrated that the world needed rapid development of a vaccine that was easily deployable around the globe. Because of previous research that laid the groundwork for this technology, an effective COVID-19 vaccine was developed, produced, approved and deployed in less than a year. This landscape-changing technology has the potential to quickly and efficiently eliminate some of healthcare’s most challenging diseases.

2. PSMA-targeted therapy



Each year, more than 200,000 Americans are diagnosed with prostate cancer — the most commonly diagnosed cancer among U.S. men. Early detection and successful imaging are critical for tumor localization, staging the disease and detecting recurrences. Prostate-specific membrane antigen (PSMA), found in high levels on the surface of prostate cancer cells, is a potential biomarker of the disease. PSMA PET uses a radioactive tracer to locate and attach to PSMA proteins, making them visible by PET imaging. This approach can be used in conjunction with CT or MRI scans to visualize where prostate cancer cells reside. In 2020, this technology received FDA approval based on phase 3 trials that showed a substantially increased accuracy for detecting prostate cancer metastases compared to conventional imaging with bone and CT scans.